Latest:
Perspectives on Treating CCA Moving Forward
A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Raajit K. Rampal, MD, PhD
Latest:
Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.
Rachel A. Freedman, MD, MPH
Latest:
Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer
Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Rachel Narozniak, MA
Latest:
Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.